Can You Take Codeine with Pregabalin?

Severity assessment

Major. Concomitant use significantly increases the risk of severe central nervous system depression, including life-threatening respiratory depression, profound sedation, coma, and death.

Mechanism (plain English)

Both codeine and pregabalin affect the central nervous system (CNS), which controls vital functions like breathing and consciousness. Codeine is an opioid painkiller that works by binding to opioid receptors in the brain and spinal cord, reducing pain signals and causing sedation. Pregabalin, a gabapentinoid, works by calming overactive nerve cells, which can also lead to drowsiness and reduced brain activity. When taken together, their individual CNS depressant effects are amplified, leading to a synergistic effect that can severely slow down breathing and decrease alertness.

Evidence level

Regulator-flagged. The Therapeutic Goods Administration (TGA) [1], European Medicines Agency (EMA) [2], and U.S. Food and Drug Administration (FDA) [3] have issued warnings or updated product information regarding the risks of co-administering gabapentinoids (like pregabalin) with opioids (like codeine).

Top regulator advisories (cite verbatim or close paraphrase)

• TGA (Australia): "Caution is advised when prescribing pregabalin or gabapentin concomitantly with opioids due to risk of central nervous system (CNS) depression. Concomitant use of opioids may result in severe sedation, respiratory depression, coma and death." [1]
• MHRA / NICE (UK): The NHS advises that "For safety, tell your doctor before you start taking pregabalin if you're taking: strong opioid painkillers such as morphine, codeine or oxycodone; medicines that make you feel sleepy or dizzy – pregabalin can make these side effects worse." [4]
• FDA / CDC (US): The FDA issued a Drug Safety Communication warning that "serious breathing difficulties may occur in patients using gabapentin or pregabalin who have respiratory risk factors and are taking other medicines that can depress the central nervous system, such as opioid pain medicines." [3]
• EMA (Europe): Scientific conclusions for codeine state that "In view of available literature data on the interaction between opioids and gabapentinoids (gabapentin and pregabalin)... an update of the section 4.5 of the SmPC is warranted to reflect interactions with gabapentinoids." The updated SmPC warns that gabapentinoids "may result in respiratory depression, hypotension, profound sedation, coma or death." [2]

Clinical risk factors that elevate the danger

• Pre-existing respiratory conditions: Conditions like chronic obstructive pulmonary disease (COPD) or sleep apnea increase vulnerability to respiratory depression.
• Elderly patients: Older individuals may be more sensitive to the CNS depressant effects of both medications.
• Higher doses: Increased dosages of either codeine or pregabalin, or both, heighten the risk.
• Concomitant use of other CNS depressants: Alcohol, benzodiazepines, or other sedatives further amplify the risk of CNS depression.
• History of substance use disorder: Patients with a history of opioid or gabapentinoid misuse are at higher risk of abuse and dependence, which can lead to overdose.
• Rapid dose escalation or abrupt discontinuation: Sudden changes in dosage can lead to adverse effects or withdrawal symptoms.

What a patient should be told

• The risk: Taking codeine and pregabalin together can make you very drowsy, dizzy, and can dangerously slow down your breathing. This can be life-threatening.
• Do not stop suddenly: Never stop taking these medications suddenly without talking to your doctor first, as this can cause unpleasant withdrawal symptoms.
• Warning signs: Be aware of warning signs such as extreme drowsiness, confusion, shallow breathing, difficulty waking up, or feeling faint. If you experience these, seek immediate medical attention.
• Safer alternatives: Discuss with your doctor or pharmacist if there are alternative pain management strategies or if your doses need to be adjusted to minimize risks.
• Urgent care triggers: If you or someone you know experiences severe difficulty breathing, unresponsiveness, or extreme sedation, call emergency services immediately.

Top 3 sources (with full citation)

1. Therapeutic Goods Administration (TGA). Pregabalin and gabapentin: Safety advisory - enhanced warnings relating to abuse and dependence. 1 February 2021. Available at: https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/pregabalin-and-gabapentin
2. European Medicines Agency (EMA). Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) for codeine. 30 November 2025. Available at: https://www.ema.europa.eu/en/documents/psusa/codeine-cmdh-scientific-conclusions-grounds-variation-amendments-product-information-timetable-implementation-psusa-00000843-202501_en.pdf
3. U.S. Food and Drug Administration (FDA). FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin and pregabalin (Neurontin, Gralise, Horizant, Lyrica, Lyrica CR). 19 December 2019. Available at: https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication
4. NHS. Taking pregabalin with other medicines and herbal supplements. 20 January 2026. Available at: https://www.nhs.uk/medicines/pregabalin/taking-pregabalin-with-other-medicines-and-herbal-supplements/

Notes for the reviewing pharmacist

The interaction between opioids and gabapentinoids, including codeine and pregabalin, is a significant and evolving area of concern. While the primary risk is CNS depression, particularly respiratory depression, the potential for misuse, abuse, and dependence is also high. Pharmacists should be vigilant in identifying patients at risk, especially those with a history of substance use disorder, respiratory compromise, or those on multiple CNS depressants. Patient education is crucial, emphasizing the additive sedative effects and the importance of not self-adjusting doses. Monitoring for signs of overdose and ensuring appropriate tapering strategies upon discontinuation are also key considerations. The TGA, EMA, and FDA have all highlighted these risks, underscoring the regulatory consensus on the severity of this interaction. The NHS guidance provides consumer-friendly advice that can be adapted for patient counseling.